3SBio Prepares For Larger Than Expected Price Cuts; Enters Dialysis Market With DaVita Deal: China Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
As price cuts loom, China’s top biotech looks to fuel EPO sales in China by teaming up with a leading U.S. dialysis provider, in a deal reminiscent of Amgen’s steps in the U.S.
You may also be interested in...
Affymax Plans For Peginesatide Launch
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma